click below
click below
Normal Size Small Size show me how
Vet 126 Midterm 2
| Question | Answer |
|---|---|
| CBC | evaluation of whole blood consisting of its cellular and noncellular components |
| PCV | determines the percentage of RBC to the total volume of blood |
| RBC | synthesize hemoglobin, transport O2 from lungs to tissues, transport waste from cells to lungs |
| WBC | protect the body from foreign microbes and toxins |
| platelet function | hemostasis |
| major mechanisms for hemostasis | vascular spasm, platelet plug, coagulation |
| plasma | noncellular portion of unclotted blood |
| albumin | most common protein, produced in liver, preserves osmotic pressure between blood and tissues |
| globulin | transport lipids and hormones, helps trap and destroy invaders |
| fibrinogen | essential clotting protein |
| serum | noncellular portion of clotted blood |
| hypoproteinemia | decrease of total protein |
| azotemia | presence of abnormally high levels of urea or other nitrogen-containing compounds in the blood |
| normal color of plasma | colorless to straw |
| abnormal colors of plasma | red, white, yellow |
| reasons for protein losses | excessive bleeding from intestinal or urinary tract, malnutrition/starvation, liver disease, parasitism |
| pre-renal azotemia | elevation of nitrogen waste in the blood that is going to kidney but kidney function is OK |
| primary renal azotemia | elevation of nitrogen waste in the blood due to poor kidney disease |
| post-renal azotemia | elevation of nitrogen waste in the blood due to an obstruction preventing the elimination of nitrogenous waste but kidney function is OK |
| electrolytes | calcium, phosphorous, sodium, potassium, chloride |
| urine specific gravity | reflects the kidney's ability to conserve water, evaluation of the urine concentrating ability of the kidney, density of urine compared to density of water |
| parts of blood separated in microhematocrit tube | RBC, buffy coat, plasma |
| important structures evaluated in a chest radiograph | lungs, heart, diaphragm, airway patency |
| Class I patient physical status | normal healthy animals, no underlying disease |
| Class II patient physical status | animals with slight to mild systemic disturbances, animals able to compensate, no clinical signs of disease |
| Class III patient physical status | animals with moderate systemic disease or disturbances, mild clinical signs |
| Class IV patient physical status | animals with preexisting systemic disease or disturbances of a severe nature |
| Class V patient physical status | surgery often performed in desperation on animals with life-threatening systemic disease or disturbances not often correctable by surgery, includes all moribund animals not expected to survive 24 hours |
| patient preparation for anesthesia | correcting pre-existing problems, bathing/grooming, permission forms signed, proper patient ID, proper procedure verification, fasting prior to anesthesia, general parameters, urination/defecation, pre-medications, IV catheterization, fluid therapy |
| correcting pre-existing problems | infections, metabolic system disturbances, parasites, nutrition, etc. |
| importance and uses of IV catheterization | ease of administration, multiple drug doses, rapid administration, emergency port, fluid therapy, constant infusions, partial dose and dose to effect |
| evaluation of hydration status | PCV, skin turgor, TPP, position of eye in orbit, mucous membrane moistness, CRT, urine specific gravity |
| crystalloids | substance which in solution passes readily through animal membranes, diffuses from the intravascular space, 3:1 ratio, most common, maintenance for surgical/anesthetic procedures |
| colloids | resist diffusion, provide oncotic pressure, confined to intravascular space, 1:1 ratio |
| administration rates for daily maintenance | 30-40 mL/lb/day |
| administration rates for anesthetic maintenance | 5-10 mL/lb/hr in small animal, 3-5 mL/lb/hr in large animal |
| administration delivery set sizes | 10, 15, 60 gtts/mL |
| cellular receptor | a molecular structure or site on the surface or inside a cell that binds with a substance; receptor activation usually results in a function or effect |
| agonist | a substance that can combine with a cell receptor to produce a reaction typical for that substance; mimics job of receptor |
| antagonist | a substance that can combine with a cell receptor to block the effect of an agonist; no activity at receptor |
| partial agonist/antagonist | a substance that can combine with a cell receptor, is able to block a pure agonist but has some effects of the agonist to a lesser degree |
| rationale for pre-medications | enhance patient comfort, reduce untoward effects of general anesthesia, decrease amount of anesthetic used, management of non-anesthetic patients |
| schedule of controlled drugs | I is more prone to abuse than V |
| most commonly used schedule of controlled drugs in veterinary medicine | schedules III and IV |
| phenothiazines | commonly used agents for sedation, can be used in combination with other agents, variety of routes of administration |
| Acepromazine | neurolept agent, affects the RAC of the brain, antiemetic, antiarrhythmic, antihistamine, reduces threshold to seizure, peripheral vasodilation, splenic congestion, decreased platelet function, excitation, protrusion of nictitans, relaxes urinary bladder |
| RAC | conscious activity, body temperature, BMR, emesis, vasomotor tone, alertness |
| benzodiazepines | release endogenous GABA, antianxiety, calming, skeletal muscle relaxation/ataxia, anticonvulsant, amnestic, can cause decrease in inhibitions, metabolized by the liver, excreted by the kidney |
| Diazepam | may absorb to plastic, light sensitive, causes precipitates to form, slow IV injection, appetite stimulant/hepatic failure in cats, ataxia, contradictory response, acute control of seizures |
| Midazolam | water soluble, given IM, excitation, combination esp. with narcotics, minimal cardiopulmonary effects, transient resp. depression, paradoxical effects, no analgesia |
| Xylazine | most commonly used thiazine derivative, IM/IV, young healthy patients, has reversal agent, 20 minute analgesia, many side effects, muscle relaxation, cannot be used with epinephrine, increased blood glucose, vomiting, bloat, depresses thermoregulation |
| Medetomidine | dog only, less affinity for alpha-1 receptors, greater potency, less side effects, IM/IV, combination with ketamine, opioids, atropine, glycopyrrolate, diuretic |
| Detomidine | horses, relieves GI/abdominal/colic pain, fatal drug interaction with sulfa antibiotics |
| Dexmedetomidine | isomer of medetomidine |
| organs containing opioid receptors | brain, spinal cord, GI, urinary, smooth muscle |
| use of opioids | derived from morphine, analgesia, neurolept analgesia, respiratory depression, thermoregulation, GI effects, addiction, bradycardia, hypotension, increased intracranial pressure, cough suppression, increased response to noise, miosis, mydriasis, sweating |
| neurolept analgesia | use of opioid+tranquilizer, used to induce general anesthesia |
| Oxymorphone | 10x more potent than morphine, hyperexcitability in cats |
| Hydromorphone | 5x more potent than morphine, relatively safe for all species |
| Fentanyl | 250x more potent than morphine, limit to where transdermal patch can be placed |
| Meperidine | 1/8th potency of morphine, severe hypotension if given too quickly, irritating if given SQ, horses experience tachycardia/profuse sweating/PVC |
| Buprenorphone | 30x more potent than morphine, may not see full effect in some species |
| Butorphanol | 4-7x more potent than morphine, tolerance build up with sequential use |
| parasympatholytic medication | block acetylcholine receptors, block parasympathetic effects, caution with patients with heart muscle disease, increased heart rate, bronchodilation, decraesed secretions |
| pain scale | 1 is less painful than 9 |
| preemptive analgesia | delivery of an analgesic prior to the painful procedure, decreases the buildup of chemical mediators of pain |
| steroids | block the action of phospholipase, stabilize cell membranes and make them less fragile, decrease inflammatory pathway, cannot use chronically |
| NSAIDs | non-steroidal anti-inflammatory drugs, aspirin-like, block formation of arachidonic acid into prostaglandins, block cyclooxygenase activity, target cyclooxygenase II |
| neutraceuticals | essential fatty acids, plant/animal sources, increase caloric intake |
| antihistamines | competitive antagonist to histamine at tissue receptors, do not prevent histamine release |
| balanced anesthesia | use of multiple anesthetic agents to achieve response |